Início › Linfoma › Pensilvânia › Philadelphia
Ensaios clínicos de Linfoma em Philadelphia, PA
15 estudos para Linfoma estão buscando participantes em locais em Philadelphia e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecrutandoEstudo observacional
- Children's Hospital of Philadelphia, Philadelphia
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecrutandoFase 1
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RecrutandoFase 2
- University of Pennsylvania, Philadelphia
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecrutandoFase 1/2
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecrutandoFase 1
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecrutandoFase 1/2
- Research Site, Philadelphia
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecrutandoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecrutandoFase 1
- Thomas Jefferson University, Philadelphia
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RecrutandoFase 1
- Hospital of the University of Pennsylvania, Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecrutandoFase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecrutandoFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
RecrutandoFase 1
- Children's Hospital of Philadelphia, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecrutandoFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecrutandoEstudo observacional
- Saint Christopher's Hospital for Children, Philadelphia
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RecrutandoFase 1
- University of Pennsylvania - Abramson Caner Center, Philadelphia
Ensaios de Linfoma em outras cidades
- Houston, TX34 estudos
- Boston, MA33 estudos
- New York City, NY33 estudos
- Washington, DC23 estudos
- Baldwin Park, CA21 estudos
- Chicago, IL20 estudos
- Durham, NC17 estudos
- St. Louis, MO15 estudos
- Cleveland, OH14 estudos
- Edison, NJ12 estudos
- Atlanta, GA12 estudos
- Seattle, WA12 estudos
Outros estudos em Philadelphia
- Câncer (todos os tipos)59 estudos
- Câncer de Mama56 estudos
- Câncer de Pulmão de Não Pequenas Células51 estudos
- Câncer Metastático46 estudos
- Câncer Colorretal44 estudos
- Câncer de Ovário44 estudos
- Câncer de Próstata44 estudos
- Câncer de Pulmão36 estudos
- Leucemia Mieloide Aguda34 estudos
- Insuficiência Cardíaca31 estudos
- Câncer Endometrial28 estudos
- Depressão26 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.